Ayurveda botanicals in COVID-19 management: An in silico multi-target approach

Swapnil Borse1,*, Manali Joshi2*, Akash Saggam3,4, Vedika Bhat1*, Safal Walia2, Aniket Marathe2, Sneha Sagar4, Preeti Chavan-Gautam5*, Aboli Girme5, Lal Hingorani, Girish Tillu1

1 AYUSH-Center of Excellence, Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India, 2 Bioinformatics Centre, Savitribai Phule Pune University, Pune, India, 3 Serum Institute of India Pvt. Ltd., Pune, Maharashtra, India, 4 Department of Pharmaceutical Chemistry, L. J. Institute of Pharmacy, Sarkhej, Ahmedabad, India, 5 Pharmanza Herbal Pvt. Ltd., Anand, Gujarat, India

* These authors contributed equally to this work.

Abstract

The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. Ayurvedic Rasayana therapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others, Withania somnifera (Ashwagandha), Tinospora cordifolia (Guduchi) and Asparagus racemosus (Shatavari) play an important role in Rasayana therapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents an in-silico network pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of these Rasayana botanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.
Introduction

The SARS-CoV-2 virus is responsible for causing the ongoing Coronavirus disease (COVID-19) pandemic [1]. Higher infectivity as compared to the SARS-CoV virus reported in 2003 and absence of a definite cure are the worrisome aspects of SARS-CoV-2 [2]. In the view of rapid spread in short period of time, the number of people infected globally is enormous (~over 2 million), and this poses a tremendous challenge to healthcare systems. COVID-19 has an age related skewed distribution of morbidity and an overall lethality although the numbers are changing as the disease is progressing [3]. The Centre for Disease Control and Prevention (CDC) reported that, COVID-19 patients with co-morbidities such as chronic lung diseases (e.g. asthma, COPD), hypertension, obesity, Type 2 Diabetes Mellitus (T2DM) are vulnerable to a higher mortality rate [4].

The SARS-CoV-2 virus primarily attacks lung alveoli for its replication. The Spike protein of the virus binds to Angiotensin Converting Enzyme-2 (ACE-2) receptors on the surface of type-II pneumocytes of alveolar lining, which are then internalised and the +ssRNA is released [5]. With the help of host ribosomal machinery and the RNA-dependent RNA polymerase (RdRp) enzyme SARS-CoV-2 synthesizes its polyproteins and multiplies its +ssRNA. The new copies of SARS-CoV-2 are released into the alveolar sac by destroying the infected pneumocytes. The inflammatory mediators released after pneumocyte damage recruit immune cells at the infected site. Macrophages release inflammatory cytokines into the blood leading to vaso-dilation of blood vessels increasing capillary permeability of endothelial cells. Neutrophils release reactive oxygen species (ROS) and proteases to destroy viruses which also damage normal pneumocytes and generate cellular debris in alveolar space. These inflammatory and immune responses result into alveolar consolidation leading to increased respiratory rate followed by cough. The systemic inflammatory response acts as messengers to hypothalamus to increase body temperature [6]. In some patients the cytokine response goes out of control leading to excessive collateral damage to organs with a possible progression to death [7, 8].

Presently there is no cure for the disease and the treatment is symptomatic. In some countries, patients are being treated using existing combinations of antivirals used for other viral infections [9]. Clinical evidence explaining the efficiency of these antivirals against SARS-CoV-2 are limited and not defined [10]. Therefore, for developing specific therapies as well as for boosting speed and scale of clinical evaluation WHO launched Solidarity clinical trial on April 8, 2020. This includes screening of four study treatments in comparison with standard of care. Based on available experimental data, remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon beta-1α, and chloroquine or hydroxychloroquine are the chosen study drugs [11]. For patients with co-morbidities, it is inevitable to take daily medication along with COVID-19 managing drugs. Therefore, it is required to have safe pharmacotherapy for COVID-19 that can be co-prescribed with WHO solidarity trial drugs and commonly prescribed drugs such as anti-hypertensive, anti-asthmatic and anti-diabetic. Administering plasma of a recovered patient to the critically ill COVID-19 patients also seems promising [12]. Hydroxychloroquine which is being used in many countries for COVID-19 treatment under emergency circumstances, seems to have limited beneficial evidence [13, 14]. There is indeed a great rush to find the holy grail for COVID-19 in terms of vaccines and therapeutics against SARS-CoV-2. Several pharmaceutical companies have announced clinical trials for drug and vaccine candidates. However, it may take a long time to reach the community.

Traditional medicine systems such as Ayurveda, have a holistic approach of considering mind-body-physiology to deal with disease conditions [15]. The Ayurvedic philosophy suggests delivering “a group of phytoconstituents” that holds potential to give adaptogenic, immunomodulatory effects and also act on drug targets [16–18]. Thus, in Ayurveda, “Rasayana
botanicals” are used for rejuvenation by boosting the immune system and alleviating disease condition [19–21]. Of several known botanicals *Asparagus racemosus* (AR) commonly known as Shatavari, *Tinospora cordifolia* (TC) known as Guduchi and *Withania somnifera* (WS) known as Ashwagandha, are known to modulate the immune system and possess antiviral activities [8, 19, 20, 22, 23].

The ideal COVID-19 therapy should show (a) antiviral properties against SARS-COV-2, (b) be safe for concomitantly administered drugs like anti-hypertensive, anti-diabetic, anti-asthmatics, and drugs those are used in respiratory tract infections (c) should modulate immune system with rejuvenation ability (mainly for cardio-respiratory and nervous system) (d) should show therapeutic adjuvant activity with drugs used in WHO Solidarity trials. In this work we explore if the botanicals WS, TC and AR can fill in the gap. Phytochemicals present in AR, TC and WS were identified using chromatographic techniques. A network pharmacology model was used to identify and depict the interactions of phytochemicals with molecular targets in the immune system to unravel their immunomodulatory role. Further, the phytoconstituents were docked to three molecular targets of SARS-CoV-2 to assess the potential for antiviral activity. Further, predictive tools were used to assess the potential of interactions between phytoconstituents and commonly prescribed drugs. The results present a compelling case that Ayurvedic Rasayana botanicals have the potential for immunomodulatory and antiviral activity and could be used as therapeutic adjuvant for COVID-19 management following rigorous experimentation.

**Materials and methods**

**Preparation of extracts and phytochemical characterization**

**Plant material and extract preparation.** The *Withania somnifera* (WS) roots used in the experiment were collected from Anand (GJ, India) and authenticated. A hydroalcoholic and water extraction was carried out for WS root powder. *Withania somnifera* hydroalcoholic extract (WSHA) and *Withania somnifera* water extract (WSW) were 10 and 12% in weight and stored at 4 to 8˚C for further studies. The *Tinospora cordifolia* (TC) sample was collected from Ratnagiri (MH, India) and authenticated. The stem was dried and powdered. A hydroalcoholic and water extraction was carried out, giving 6.6% and 7% yield. *Tinospora cordifolia* hydroalcoholic extract (TCHA) and *Tinospora cordifolia* water extract (TCW) were stored at 4-8˚C. The *Asparagus racemosus* (AR) roots used in the experiment were collected from Anand (GJ, India) and authenticated. The dried and pulverized AR sample (100 g) was extracted with hydroalcohol and water as *Asparagus racemosus* hydroalcoholic extract (ARHA) and *Asparagus racemosus* water extract (ARW) giving 30% and 20% yield, respectively. The voucher specimen samples were submitted, and plant authentication was done by the Botanical Survey of India Arid Zone Regional Centre Jodhpur (IN). Further, all specimens were deposited at the Department of Botany, Pharmanza Herbal Pvt Ltd, (Anand, Gujarat, IN).

**Chemicals and reagents.** The compounds used in the WS study are withanoside IV (WS1), withanoside VII (WS2), viscosalactone B (WS3), 27-hydroxywithanone (WS4), dihydrowithaferin A (WS5), withaferin A (WS6), withanoside V (WS7), 12-deoxywithastramonomolide (WS8), withanolide A (WS9), withanolone (WS10), and withanolide B (WS11). Compounds WS1 and WS9 were procured from USP (MD, USA), and compounds WS7, WS8, WS10 and WS11 were procured from phytocompounds (Bangalore, IN); compound WS6 was procured from Chromadex (CA, USA). Compounds WS (2–5) were isolated from WS’s roots in the in-house laboratory by previously reported methods.

The reference compounds used in the TC study are cordifolioside-A (TC1), 20-β-hydroxy ecdysone (TC2), tinosporaside (TC3), 8-hydroxy tinosporide (TC4), tinosporide (TC5),
columbin (TC6). Compound TC1 and TC6 were procured from Chemfaces (Hubei, CN) and compound TC2 from Chromadex (CO, USA). The compounds TC (3–5) were isolated from TC’s stems in the in-house laboratory by previously reported methods.

The reference compound used in the AR study is shatavarin-IV (AR1) was procured from Phytocompounds (Bangalore, IN). UHPLC-PDA confirmed the minimum purity of these standards as > 90% by analyzing concentrated standards (1 mg/mL) in acetonitrile and water (1:1) isocratic elution. The procurement of acetonitrile and methanol of HPLC grade was from Rankem, IN, and MS grade water was from JT Baker, FS, IN.

Instrument Condition for UHPLC–PDA study for WS, TC, and AR analysis: The instrument used for UHPLC analysis was Shimadzu Nexera X2 (Shimadzu Tech., Kyoto, Japan), consisting of a quaternary pump (LC-30AD), autosampler (SIL-30AC), column oven (CTO-20AC), and data analyzed using the Lab Solution software (Version 6.80).

Chromatographic conditions for UHPLC–PDA analysis for WS compounds. The WS compounds were separated on a Phenomenex Luna 5 μm C8 (2) 100 Å column (250 mm x 4.6 mm x 5 μm). The column temperature was maintained at 35˚C. The mobile phase was composed of water (A) and acetonitrile (B) with a gradient elution program with a detection wavelength of 227 nm with a run time of 50 min [24].

Preparation of the standard solution. The stock solution of each of the standard compounds WS (1–11) was prepared with a concentration of 100 μg/mL in methanol. Five different concentration levels of each compound were injected in triplicate to prepare the calibration curves. The calibration curves were formed in the range of between 1–150 μg/mL for compounds WS (1–4) and WS (6–11) and 1–100 μg/mL for compound WS5. All the working solutions were stored at 4˚C.

Sample solutions. The samples were weighed and diluted with methanol (100 mg/10 mL), followed by sonication for 30 min. This sample solution was passed through a 0.22 μm filter and injected into the UHPLC system for analysis.

Chromatographic conditions for UHPLC–PDA analysis for TC compounds. For TC compounds, a Phenomenex Luna C18 (2) 100Å column (4.6 X 250 mm, 5.0μm) was used for separation. The mobile phase consisted of solvent A (0.1% phosphoric acid in water) and solvent B (acetonitrile). The gradient elution at a flow rate of 1.00 mL/min with injection volume was set at 20 μL, and the detection wavelength was set at 210nm. The run time of the method was set at 45 min [25].

Preparation of the standard solution. The stock solution of TC (1–5) compounds (500 μg/mL) were separately prepared by dissolving 1.0 mg of accurately weighed standards in 5 mL methanol to make up the volume up to 10 mL methanol in an amber-coloured volumetric flask. The stock solution was further diluted as per the requirement for preparing a working solution (methanol: water). Five different concentration levels of each compound were injected in triplicate to prepare the calibration curves. The range of calibration curves was between 0.5–120 μg/mL for Shatavari. The working solutions were stored at 4˚C.

Sample solutions. The sample extraction method was employed to extract the target analytes from the TC. The samples were accurately weighed, and methanol: water (70:30) (200 μg/10 mL) was added, followed by sonication for 30 min. This sample solution was passed through a 0.22 μm filter and injected into the UHPLC system for analysis.

Chromatographic conditions for UHPLC–PDA analysis for AR compounds. For AR analysis, Shimadzu C18 (2) 100Å column (4.6 X 250 mm, 5.0 μm) was used for separation. The mobile phase consisted of solvent A (water) and solvent B (acetonitrile). The gradient elution at a flow rate of 1.00 mL/min with injection volume was set at 20 μL, and the detection wavelength was set at 210nm. The run time of the method was set at 55 min [26].
Preparation of the standard solution. The stock solution of shatavarin-IV RS was prepared with a concentration of 250 μg/ml in methanol. Five different concentration levels were injected in triplicate to prepare the calibration curves in the range of between 3.9–250 μg/mL for shatavarin-IV. The working solutions were stored at 4°C for further use.

Sample solutions. The simple and rapid method was employed to extract the target analytes from the AR. The samples were accurately weighed, and methanol (300μg/ 10 mL) was added, followed by sonication for 30 min. This sample solution was passed through a 0.22 μm filter and injected into the UHPLC system for analysis.

Application of UHPLC-PDA in the quantification of samples by external standard calibration. The water and hydroalcoholic extracts of WS, TC, and AR were analyzed (n = 3) by UHPLC-PDA method as in the above paragraphs. The quantification is done by an external standard calibration method. Experimental data analysis and parameter calculation were achieved using Office Excel 2010 (Microsoft, Redmon, WA, USA).

Mass spectrometric analysis of the WS, TC and AR extracts. Whereas MS was carried out at Bioanalytical Technologies Pvt. Ltd., Pune and Central Instrumentation facility (CIF), Savitribai Phule Pune University, Pune. The MS grade Methanol, Water and Formic acid were used as solvents. The MS: 4000 QTrap were used with ESI Q1 Positive mode. 10 mg of each sample was weighed in a 10 ml volumetric flask. The sample was dissolved up to the mark with methanol: water (80:20) V/v + 0.1% formic acid. The sample was filtered through 0.22-micron filter. 1ml of filtrate was transferred to 10 ml volumetric flask and volume was made-up with HPLC grade methanol and filtered through 0.22 micron before injection.

Network pharmacology

The network pharmacology approach was followed to explore the role of Rasayana botanicals i.e. AR, TC, and WS in immunomodulation. Briefly, the qualitatively characterized phytochemicals (also referred as bioactives) from extracts were queried in PubChem database (https://pubchem.ncbi.nlm.nih.gov/) to obtain sdf files [27]. These files were uploaded to BindingDB database (https://www.bindingdb.org/bind/index.jsp) to retrieve putative protein targets of uploaded bioactives that had a similarity score of with ≥0.7 with co-crystalized ligands [28]. Gene names for compiled human protein targets were retrieved from UniProt Knowledgebase (http://www.uniprot.org/) [29]. Simultaneously, the KEGG pathway database (https://www.genome.jp/kegg/pathway.html) was mined to obtain proteins/genes involved in human immune pathways [30]. The KEGG database enlists twenty pathways related to immune system. The entire data was collected and analysed in Microsoft Excel to identify putative immune-associated protein targets of bioactives of AR, TC, and WS. The network of available data was constructed with eloquent representation using Cytoscape 3.7.2 (https://cytoscape.org/) software [31].

Molecular docking and simulations

All 31 phytoconstituents, including 11 from AR, 10 from TC and 10 from WS were considered in this study. All 31 compounds were downloaded from Pubchem in sdf format including 3D coordinates [27]. Three drug targets of SARS-CoV-2 were considered namely, the Receptor Binding Domain of Spike Protein (RBD), the Main Protease (Mpro) and the RNA dependent RNA polymerase (RdRp). Docking was performed with AutoDock 4.2.6 assembled in the PyRx 0.8 Virtual Screening Tool [32, 33]. For the Main protease, the crystal structure of the protease complexed with 2-cyclohexyl-[N]-pyridin-3-yI-ethanamide (GWS) (PDB ID: 5R84 Chain A, resolution 1.83Å) was considered for structural studies. A grid box was prepared with dimensions 60×60×60 Å centred on the protein around residues which interacted with
co-crystallized ligand GWS representing pockets S1-S3, with grid spacing of 0.375Å. For the RNA-dependent RNA polymerase, the PDB ID: 6M71 Chain A, resolution 2.90 Å, was considered for structural studies [34]. A grid box of dimensions 100×100×100Å with grid spacing of 0.375Å was centred around the RNA binding site. The cryoEM structure of Receptor Binding Domain of Spike protein with ACE2-B0AT1 complex (PDB ID: 6M17 Chain E, resolution 2.90 Å) was considered for structural studies [35]. A grid box was prepared with dimensions 90×90×90Å and spacing 0.375Å and was centred on the protein residues: Lys417, Tyr453, Gln474, Phe486, Gln498, Thr500 and Asn501. Prior to docking, all compounds were subjected to energy minimization using the inbuilt Open Babel module in Pyrx [36]. 50 docking runs were performed for each phytochemical with each drug target, with a population size of 150 and 250000 energy evaluations. All the other algorithm parameters were kept default. The final pose of the phytoconstituents was selected based on its docking score. The grid dimensions for each protein system are given in S2 Table in S1 File.

Simulations of the protein-ligand complexes were performed using GROMACS version 2019.6 [37]. Parameters for the ligand were obtained from cgenff using Ligand Reader & Modeller module of CHARMM-GUI [38] while CHARMM36 [39] parameter set was used for protein. Briefly, the complexes were solvated using explicit water and ions were added to neutralize the systems. Systems were minimized using Steepest Descent algorithm followed by equilibration using NVT (constant number of molecules, Volume and Temperature) and NPT (constant number of molecules, Pressure and Temperature) ensemble for 100 ps each. Berendsen method was used for temperature coupling. Pressure coupling was carried out by Parinello-Rahman method. Periodic Boundary Conditions were applied, and long-range interactions were treated using Particle Mesh Ewald (PME) method. All simulations were performed for 30 ns. Analysis was performed using standard GROMACS and VMD tools.

Predicting herb-drug interactions

Considering the COVID-19 complex pathogenesis there is concomitant administration of multiple drugs with herbs which may lead to risk of herb-drug interactions (HDIs) [40]. Therefore, the probable pharmacokinetic-pharmacodynamic herb drug interactions (HDIs) were explored based on data generated from Swiss-ADME (http://www.swissadme.ch/) [41] and available literature.

Results

A total of 31 major phytoconstituents are identified from *Withania somnifera*, *Tinospora cordifolia* and *Asparagus racemosus*

The percent yield of hydro alcoholic extract of WS, TC, and AR were found to be 10%, 6.6%, and 30% in weight respectively. The percent yield of water extract of WS, TC, and AR were 12%, 7% and 20% respectively. The detailed phytochemical characterization and standardization was done as described in methods section and data has been provided in Figs 1–9. As per the current norms for phytochemical characterization we have quantified at least 4 phytoconstituents in all the test extracts, except *Asparagus racemosus* with the help of HPLC. Whereas MS were used for qualitative presence of phytoconstituents of the respective plant extracts. The extracts were also analysed for physiochemical properties, presence of impurities and microbial load as per pharmacopeial standards. The certificate of analyses showed that presence of impurities (heavy metals) and microbial load were within acceptable limit as per pharmacopeial standards.

UHPLC–PDA quantification WS, TC, and AR samples: The fingerprinting and quantitative analysis of a standardized WS, TC, and AR extracts is a robust quality control (QC) tool.
quantitative data represents the validated analysis of bioactive samples in this research, the six bioactive extracts. Many QC laboratories are equipped with UHPLC or HPLC instruments, which facilitate routine analysis. The quantification was done against linearity and calibration curve from UHPLC-PDA for WS, TC, and AR compounds by external standard method [42]. The WSHA and WSW samples confirmed the presence of eleven specific withanolides and withanosides in it. TCHA and TCW were quantified for six specific bioactive TC markers, which were found to present different concentrations. The ARHA and ARW were found to contain shatavarin-IV as major phytochemical in samples (Table 1).

Whereas MS based qualitative analysis helped to predict other additional phytoconstituents that may be present in these extracts. Briefly, a total of 31 phytoconstituents were identified from these plant extracts using HPLC and MS. The AR extract showed the presence of Asparagus-A, Asparanin-A, Isoagatharesinol, Muzanzagenin, Rutin, Shatavarin-I, Shatavarin-IV, Shatavarin-IX, Shatavarin-VI, Shatavarin-VII, and Shatavarin-X. The TC extract showed the presence of 20-Hydroxy Ecdysone, Berberine, Columbamine, Columbin, Magnoflorine, Menisperine, Syringin, Tinocordiside, Tinosporaside and Tinosporide. WS extract showed the
presence of 12-Deoxywithastramonolide, 27-Hydroxywithanone, Ashwagandhanolide, Witha-
coagin, Withaferin, Withanolide-A, Withanolide-B, Withanone, Withanoside-IV, Withano-
side-V. The structures of 31 phytoconstituents are given as S3 Table in S1 File. These
phytoconstituents were used for further studies.

Network pharmacology reveals multiple associations of phytoconstituents with immune pathways

Rasayana botanicals have immunomodulatory potential and help in rejuvenation of body
homeodynamics [43, 44]. The bioactives i.e. Shatavarins of AR, Tinosporides of TC, and With-
anolides of WS are known to play crucial role in immunomodulation [8, 20, 45]. According to
traditional medicine or Ayurveda principles, the synergistic effect of bioactive combination in
an extract strengthens physiological immunity superior than a single molecule [46]. To assess
the immunomodulatory potential of the experimentally identified 31 phytoconstituents from
AR, TC and WS a network pharmacology approach was followed [47]. As a first step, potential protein targets of bioactives were identified using the BindingDB server. The targets identified were mapped to known immune pathways that were extracted from the KEGG database and plotted using Cytoscape. The retrieved data showed total 29 bioactives from Rasayana botanicals associated with 306 unique human protein targets. Of these, 53 protein targets of 28 bioactives were found to be involved in 20 immune pathways referred as immune targets (Fig 10).

The detailed mapping of phytoconstituents from each plant with targets and the number of associations reveals that bioactives from Withania somnifera show the largest number of associations (Fig 11A). The distribution of immune targets amongst Rasayana botanicals is shown Fig 11.

More specifically, we analysed the data to evaluate involvement of Rasayana botanicals in immune pathways by combinations of bioactives and targets in a particular immune pathway (Fig 11). The analysis showed involvement of AR in Th17 cell differentiation with 24 associations between 8 bioactives and 6 targets. AR was also found to be involved in IL-17 signalling.

Fig 3. UHPLC−PDA chromatogram of reference compounds (RS) and samples with detection for (C) Asparagus racemosus at 210 nm for AR-1 in the (C1) reference compound AR1(C2) ARHA (C3) ARW; where shatavarin-IV (AR1).

https://doi.org/10.1371/journal.pone.0248479.g003
with 13 associations between 9 bioactives and 7 targets. Data analysis showed association of TC with chemokine signalling with 13 associations between 7 bio-actives and 5 targets. TC was also found associated with few other pathways such as NOD-like receptor signalling, leukocyte trans-endothelial migration, and NK cell mediated cytotoxicity by moderate bioactive-target associations. The analysis also retrieved multimodal involvement of WS in immunomodulation through various pathways. It was found to be associated with chemokine signalling with 66 associations between 9 Withanolides and 11 immune targets. WS was also found to be associated with FC-gamma R-mediated phagocytosis and receptor signalling (NOD-like and c-type lectin) by 54, 55, and 46 bioactive-target associations. Furthermore, WS was also found
to be associated with T cell differentiation, NK cell cytotoxicity and signalling pathways of IL-17, TCR and BCR etc. The multidimensional correlation with immune pathways underlines the importance of WS in managing the immunopathology of COVID-19 by improving T cell, B cell and NK cell function and hence anti-viral immunity.

AR, TC, and WS showed association with 18, 19, and 20 immune pathways through involvement of 19, 25, and, 27 immune targets respectively (Fig 11). The 7 common targets associated with all three Rasayana botanicals are Bcl-2-like protein 1 (BCL2L1), glycogen synthase kinase-3 beta (GSK3B), Interleukin-2 (IL2), prostaglandin G/H synthase 1 and 2 (PTGS1 and PTGS2), prothrombin (F2), and signal transducer and activator of transcription 3 (STAT3). These
Fig 8. Mass spectrometer fingerprint of *Asparagus racemosus* water extract (ARW).

https://doi.org/10.1371/journal.pone.0248479.g008

Fig 9. Mass spectrometer fingerprint of *Asparagus racemosus* hydro-alcoholic extract (ARHA).

https://doi.org/10.1371/journal.pone.0248479.g009
Immune targets are found to be involved in 11 different immune pathways including chemokine and specific receptor signalling (NOD-like, C-type lectin, BCR, and TCR), immune cell differentiation (Th1, Th2, and Th17), platelet activation and coagulation cascade, and intestinal IgA production. These results highlight the ability of Rasayana botanicals to modulate multiple immune pathways and have implications for immunomodulatory potential of these botanicals.

Phytoconstituents show potential of antiviral activity

To identify if any of the 31 phytoconstituents might possess the potential for antiviral activity against SARS-CoV-2, they were docked to three important drug targets of the virus, the Spike protein, the Main Protease and the RNA dependent RNA polymerase. Molecular docking was performed using the protocol as described in the methods section.

Several phytoconstituents are predicted to possess good affinity for the Main Protease (MPro)

There were 84 crystal structures of the Main Protease (MPro) in the PDB at the time of writing this manuscript. The largest share of the deposition is a series of MPro crystal structures obtained by fragment screening. This indicates that the binding site of MPro is druggable. The MPro is known to be functional as a homodimer and has a heart-like shape. The protein has one active site per monomer. The active site contains the catalytic cysteine-Cys145, that performs the proteolysis reaction. The structure, PDB ID: 5R84, solved at a resolution of 1.83 Å was chosen for this study. In this structure, the protease is co-crystallized with the fragment cyclohexyl-N-(3-pyridyl) acetamide (Z31792168) which is seen to bind in the S1-S3 pocket of the protease.

| Sr.no. | Analytes                  | WSHA | WSW  |
|-------|---------------------------|------|------|
| 1     | Withanoside-IV            | 0.4202 | 0.0999 |
| 2     | Withanoside-VII           | 0.3180 | 0.0881 |
| 3     | Viscosalactone-B          | 0.0348 | 0.0154 |
| 4     | 27-Hydroxywithanone       | 0.0002 | 0.0003 |
| 5     | Dihydrowithaferin A       | 0.0042 | 0.0192 |
| 6     | Withaferin-A              | 0.4117 | 0.1096 |
| 7     | Withanoside- V            | 0.4511 | 0.0288 |
| 8     | 12-Deoxywithastramonolide | 0.0716 | 0.0600 |
| 9     | Withanolide-A             | 0.0974 | 0.0889 |
| 10    | Withanine                 | 0.0000 | 0.0002 |
| 11    | Withanolide-B             | 0.0534 | 0.0093 |

| Sr.no. | Analytes                  | TCHA | TCW  |
|-------|---------------------------|------|------|
| 1     | Cordifolioside A          | 0.0026 | 0.017 |
| 2     | 20-B-hydroxy ecysone      | 0.6160 | 0.386 |
| 3     | Tinosporaside             | 0.0043 | 0.028 |
| 4     | 8 Hydroxy tinosporide     | 0.655  | 0.121 |
| 5     | Tinosporide               | 0.7817 | 0.066 |
| 6     | Columbin                  | 0.133  | 0.002 |

| Sr.no. | Analytes                  | ARHA | ARW  |
|-------|---------------------------|------|------|
| 1     | Shatavarin-IV             | 0.0950 | 0.0596 |

Note: The text extracts are Asparagus racemosus water extract (ARW), Asparagus racemosus hydroalcoholic extract (ARHA), Tinospora cordifolia water extract (TCW), Tinospora cordifolia hydroalcoholic extract (TCHA), Withania somnifera water extract (WSW), Withania somnifera hydroalcoholic extract (WSHA).

https://doi.org/10.1371/journal.pone.0248479.t001
The S1 pocket is characterized with the presence of His163, Glu166, S2 with Cys145 and S3 is known as the aromatic wheel and includes Phe181 and His41. Thus, in our studies we placed the docking grid over the S1-S3 pocket. Initially, the co-crystallized ligand was separated and docked to check if Autodock was able to reproduce the binding mode. The docked pose showed an RMSD of 0.46 Å with the crystal structure pose and a docking score of -6.2 kcal/mol (Fig 12A and 12B). A detailed study of interactions revealed that the carbonyl group of Z31792168 shows a H-bond with Glu166 in the S1 pocket. The docked pose showed an RMSD of 0.46 Å with the crystal structure pose and a docking score of -6.2 kcal/mol (Fig 12A and 12B). A detailed study of interactions revealed that the carbonyl group of Z31792168 shows a H-bond with Glu166 in the S1 pocket. The cyclohexyl moiety of the ligand has hydrophobic interactions with Met165, His41, His164, Arg188 and Gln189 residue in the S3 pocket. The pyridine ring scaffold shows hydrophobic interactions with Phe140 and His163 in the S1 pocket. All these interactions are in line with the crystallographic pose.
Thereafter, 31 phytoconstituents were docked to the binding site. The results are compiled in Table 2. It is a frequent observation that compounds with a docking score better than -6 kcal/mol have a higher probability of being active in vitro and in vivo and hence use this score as a cutoff [48]. In our study we observed that, 18 out of 31 phytoconstituents have a docking score better than -6 kcal/mol. The best docking score -9.9 kcal/mol was observed for Ashwagandhanolide. Many other phytoconstituents like Withacoagin, Withaferin and Withanone are observed to have docking scores close to the -9 kcal/mol. However, a point to be noted is that some of these phytoconstituents are large molecules and hence the docking scores may appear to be inflated due to size and the proportionately larger

Fig 11. Analysis of bioactive-target associations in immune pathways. (A) The figure depicts the involvement of AR, TC, and WS in pathways of human immune system. The represented association is number of connecting combinations between bioactives and their targets in a particular pathway. (B) The table lists all immune targets of AR, TC, and WS.

https://doi.org/10.1371/journal.pone.0248479.g011
Fig 12. Interaction of (A and B) cyclohexyl-N-(3-pyridyl)acetamide (Z31792168), (C and D) Columbin and (E and F) Tinocordiside with Mpro: In the left panel the protein is shown in a surface representation colored by atom while the ligand is shown in stick representation. The right panel is a 2D interaction plot of the receptor with the inhibitors.  
https://doi.org/10.1371/journal.pone.0248479.g012
number of interactions. Ligand efficiency is a measure of the activity corrected for the ligand size [49]. A calculation of the ligand efficiency indicates that the co-crystallized ligand, Z31792168, has a ligand efficiency of -0.4. Among the phytoconstituents, the highest ligand efficiency, -0.3, is observed for Columbin. Several other phytoconstituents have comparative ligand efficiency namely, Tinocordiside, Magnoflorine and Isoagatharesinol. Columbin and Tinocordiside not only have docking scores close to -8 kcal/mol but also have high ligand efficiencies. Similarly, Withacoagin, Withaferin, Withanolide-A, B and Withanone have good docking scores and ligand efficiencies. Interestingly, all compounds also follow Lipinski Rules which helps to distinguish between drug like and non-drug like molecules. A detailed study of interactions of M\textsuperscript{pro} with Columbin (Fig 12C and 12D) revealed that the tetrahydrofuran part of the ligand forms hydrogen bonds with His163 in the S1 pocket, while the hydroxyl and carbonyl groups form hydrogen bonds with Gln89 and electrostatic interactions with Met49. Further the ligand makes vDW interactions with several residues in the S2 and S3 pockets in a manner like Z31792168. A short simulation of

Table 2. Docking results of the phytoconstituents from AR, TC and WS.

| Ligand              | Heavy atoms | Main Protease Docking Score | Ligand efficiency | Spike Glycoprotein (RBD) Docking Score | Ligand efficiency | RNA dependent RNA polymerase Docking Score | Ligand efficiency |
|---------------------|-------------|-----------------------------|-------------------|---------------------------------------|-------------------|------------------------------------------|-------------------|
| Asparagamine-A      | 28          | -7.1                        | -0.25             | -5.4                                  | -0.19             | -6.3                                     | -0.22             |
| Asparanin-A         | 52          | -6.3                        | -0.12             | -5.8                                  | -0.11             | -7.5                                     | -0.14             |
| Isoagatharesinol    | 21          | -5.8                        | -0.28             | -4.6                                  | -0.22             | -5.0                                     | -0.24             |
| Muzanzagenin        | 32          | -7.6                        | -0.24             | -7.1                                  | -0.22             | -9.3                                     | -0.29             |
| Rutin               | 43          | -5.3                        | -0.12             | -3.3                                  | -0.08             | -3.6                                     | -0.08             |
| Shatavarin-I        | 74          | -1.1                        | -0.01             | -1.7                                  | -0.02             | -3.3                                     | -0.04             |
| Shatavarin-IV       | 62          | -2.7                        | -0.04             | -6                                    | -0.1              | -6.3                                     | -0.10             |
| Shatavarin-IX       | 63          | -0.6                        | -0.01             | -5.4                                  | -0.09             | -6.7                                     | -0.11             |
| Shatavarin-VI       | 62          | -4.9                        | -0.08             | -4.6                                  | -0.07             | -7.5                                     | -0.12             |
| Shatavarin-VII      | 62          | -6.6                        | -0.11             | -5.7                                  | -0.09             | -6.3                                     | -0.10             |
| Shatavarin-X        | 66          | -0.4                        | -0.01             | -4                                    | -0.06             | -5.2                                     | -0.08             |
| 20-HydroxyEcdysone  | 34          | -6.4                        | -0.19             | -4.8                                  | -0.14             | -5.7                                     | -0.17             |
| Berberine           | 25          | -6.3                        | -0.25             | -5                                    | -0.2              | -5.7                                     | -0.23             |
| Columbamine         | 25          | -5.9                        | -0.23             | -4.6                                  | -0.18             | -5.4                                     | -0.22             |
| Columbin            | 26          | -7.9                        | -0.30             | -5.8                                  | -0.22             | -6.8                                     | -0.26             |
| Magnoflorine        | 25          | -7.0                        | -0.28             | -5.2                                  | -0.21             | -6.6                                     | -0.27             |
| Menisperine         | 26          | -6.9                        | -0.27             | -5.2                                  | -0.2              | -6.2                                     | -0.24             |
| Syringin            | 26          | -5.3                        | -0.20             | -3                                    | -0.11             | -4.2                                     | -0.16             |
| Tinocordiside       | 28          | -8.1                        | -0.29             | -5.1                                  | -0.18             | -6.6                                     | -0.24             |
| Tinosporaside       | 35          | -7.9                        | -0.23             | -5.7                                  | -0.16             | -6.6                                     | -0.19             |
| Tinosporide         | 27          | -4.3                        | -0.16             | -4.6                                  | -0.17             | -4.4                                     | -0.16             |
| 12-Deoxywithastramonolide | 34       | -8.1                        | -0.24             | -6.9                                  | -0.2              | -7.9                                     | -0.23             |
| 27-Hydroxywithanone | 35          | -8.6                        | -0.25             | -7.6                                  | -0.22             | -7.6                                     | -0.22             |
| Ashwagandhanolide    | 69          | -9.9                        | -0.14             | -10                                   | -0.14             | -10.2                                    | -0.15             |
| Withacoagin         | 33          | -8.8                        | -0.27             | -7.6                                  | -0.23             | -8.8                                     | -0.27             |
| Withaferin          | 34          | -8.8                        | -0.26             | -6.9                                  | -0.2              | -8.5                                     | -0.25             |
| WithanolideA        | 34          | -8.5                        | -0.25             | -6.7                                  | -0.2              | -8.2                                     | -0.24             |
| WithanolideB        | 33          | -8.3                        | -0.25             | -7.4                                  | -0.22             | -8.9                                     | -0.27             |
| Withanone           | 34          | -8.8                        | -0.26             | -7.1                                  | -0.21             | -8.9                                     | -0.26             |
| WithanosideIV       | 55          | -5.6                        | -0.10             | -4.6                                  | -0.08             | -5.8                                     | -0.11             |
| WithanosideV        | 54          | -6.1                        | -0.11             | -5.1                                  | -0.1              | -6.0                                     | -0.11             |

https://doi.org/10.1371/journal.pone.0248479.t002
Fig 13. Interaction of (A and B) Remdesivir (C and D), Muzanzagenin and (E and F) Withanolide-B with RdRp. In the left panel the protein is shown in a surface representation colored by atom while the ligand is shown in stick representation. The right panel is a 2D interaction plot of the receptor with the inhibitors.

https://doi.org/10.1371/journal.pone.0248479.g013
this docked pose reveals that the ligand repositions but is stable in the S1-S3 binding pocket (S1 and S2 Figs in S1 File). The detailed interactions of Tinocordiside (Fig 12E and 12F) reveal that the hydroxyl groups of the β-glucose part of the ligand positioned in the S3 pocket of the protein form hydrogen bonds with the backbone of Arg188, Thr190, Glu166 and the sidechain of Gln189. The carbonyl group on the other side of the ligand forms hydrogen bonds with His 163 from the S1 pocket. Additionally, hydrophobic interactions are observed with amino acids Phe140, Asn142, His164, Met165 and Pro186.

**Several phytoconstituents are also predicted to possess good affinity for the RNA dependent RNA polymerase (RdRp)**

For the RdRp of SARS-CoV-2 the PDB ID: 6M71 was chosen for this study [34]. This is a cryoEM structure solved at a resolution of 2.9 Å. Residues 367 to 920 of the structure form the RdRp domain. The authors report that a structural comparison of the SARS-CoV-2 RdRp with that of Poliovirus (PDB ID: 3OL6) and HCV indicates that the polymerase domain adopts a conserved structural architecture. The residues Arg553, Lys545 and Arg555 form the NTP entry channel while residues Asp760 and Asp761 coordinate divalent cations that stabilize the phosphate group (the cations are absent from PDB ID: 6M71 as it is an apo structure). We placed our grid over the entire RNA binding site based on the structure of Poliovirus RdRp. Remdesivir is an ATP analog and is being evaluated as a potential treatment for SARS-CoV-2 as an inhibitor of RdRp based on results obtained for MERS and SARS-CoV [50]. Remdesivir is a prodrug whose active metabolite is GS-441524 (PubChem CID: 44468216). GS-441524 was docked to the RNA binding site. The docked results (Fig 13A and 13B) indicate that the active metabolite forms hydrogen bonds with Asp760 which is an important active site residue and with Lys621 and Tyr619. The position of the active metabolite is that of the NTP entry channel. The docking score for the metabolite is -4.28 and the ligand efficiency is -0.2. Next, 31 phytoconstituents were docked to the binding site. The results are compiled in Table 2. Withanolide-B, Withacoagin, Withanone, Ashwagandhanolide and Muzanzagenin are predicted to possess docking scores ranging from ~ -9 to 10 kcal/mol. A total of twenty-one phytoconstituents have a docking score better than -6 kcal/mol. Calculation of ligand efficiency reveals that the top binders include Muzanzagenin, Withaolide-B, Withacoagin and Magnoflorine. There are sixteen compounds with ligand efficiency better than the active metabolite. However, it is to be noted that the GS-441524 is a chain terminating nucleotide analog, while these compounds would be pure blockers. The detailed interactions of Muzanzagenin with RdRp (Fig 13C and 13D) reveal two hydrogen bonds with the critical residues Asp760 and Asp761 apart from Trp800 and non-polar interactions over the NTP entry channel with residues Arg553 Lys621, Arg623. The binding pose and interactions of Withanolide-B (Fig 13E and 13F) also show interactions with the residues in NTP entry channel and the cation coordinating residues. In particular, hydrogen bonds are observed with side chains of residues Asp623, Ser795 and Ser795 and backbone of Cys622 while non-polar interactions are observed with Phe140, Leu141, Leu167, Ala191. A short simulation of this docked pose reveals that there is a slight repositioning of the ligand in the binding pocket (S1 and S3 Figs in S1 File).

**Phytoconstituents from WS are predicted to possess good affinity for the Spike protein**

The entry of coronaviruses into cells is owing to the interaction between the clove shaped trimeric Spike viral protein with the human ACE2 receptors on the cell surface. Since this is the first and crucial point of contact between the viral protein with the human receptor this is a...
sought-after target for design of vaccine and therapeutics [51]. There are several structures of the SARS-CoV2 Spike protein with the human ACE2 protein. We chose the structure PDB ID: 6M17 for our docking studies [35]. This is a Single Particle cryoEM structure solved at a resolution of 2.9 Å. This structure represents the Receptor Binding Domain (RBD) of Spike protein with full length human ACE2. The Spike protein RBD interacts with the Peptidase Domain (PD) of the ACE2 in a 1:1 ratio. The interactions between the RBD and PD are mediated by residues Gln24, Lys417, Tyr453, Gln474, Phe486, Gln498, Thr500 and Asn501 of RBD. These

![Fig 14. Interaction of (A and B) Withacoagin and (C and D) Withanolide-B with Spike protein: In the left panel the protein is shown in a surface representation colored by atom while the ligand is shown in stick representation. The right panel is a 2D interaction plot of the receptor with the inhibitors.](https://doi.org/10.1371/journal.pone.0248479.g014)
residues are divided into three clusters, two clusters at each end and one in the center of the RBD. We placed the docking grid around all these residues to find molecules that could disrupt the contacts between RBD and PD.

The docking results with 31 phytoconstituents reveal that the compounds bind in various areas of the interface region of RBD. The top scoring compound is Ashwagandhanolide with a docking score of -10 kcal/mol. Ten phytoconstituents have a docking score better than -6 kcal/mol. Withacoagin, 27-Hydroxywithanone and Withanolide-B are predicted to have docking scores of -7.6, -7.6 and -7.4 kcal/mol respectively. The ranking based on ligand efficiency places Withacoagin at the top with a value of -0.23. Several compounds including Withanolide-B have a ligand efficiency of -0.22. Detailed analysis of the top docked pose of Withacoagin (Fig 14A and 14B) indicates that it binds over middle and terminal cluster of residues that interact with PD. The ligands form hydrogen bonds with Ser494, Tyr495 and Arg403 and vdW interactions with Phe497, Asn501, Gln493, Tyr453, Leu455 and Phe456. A short simulation of this docked pose reveals that the ligand repositions in the binding pocket (S1 and S4 Figs in S1 File). Withanolide-B only interacts with the terminal cluster of residues and shows hydrogen bonds with Thr500 and Asn501 and non-polar interactions with Tyr453, Ser494, Tyr495, Arg403, Tyr505, Gly496 and Gln498 (Fig 14C and 14D).

Predicting herb-drug interactions

The Swiss-ADME, cheminformatics platform was used to predict pharmacokinetics and drug likeliness potential of the 31 phytoconstituents. Bioavailability RADAR analysis showed, 9 phytoconstituents of TC are orally bioavailable (S5 Fig in S1 File). Out of 11 phytochemicals of AR only Muzanzagenin and Asparagamine-A were found to be orally bioavailable. For WS, except Ashwagandhanolide, Withanoside-V and Withanoside-IV all other analyzed phytochemicals were found to be orally bioavailable. The assessment of drug likeness indicates that Muzanzagenin and Asparagamine-A from AR, all analyzed phytochemicals of TC except 20-β-Hydroxy Ecdysone and Tinosporaside and all analyzed phytochemicals of WS except Ashwagandhanolide, Withanoside-V and Withanoside-IV have drug-like properties (Table 3). Further, apart from Syringin, Asparagamine-A and Isoagatharesinol all the phytoconstituents are predicted to be a substrate of P-gp transporter (Table 3). Muzanzagenin, Asparagamine-A from AR and Columbamine, Berberine, Magnoflorine, Menisperine from TC showed ability to penetrate the blood brain barrier (BBB). Log Kp (Kp in cm/s) is skin permeation coefficient that assesses ability of test molecule to permeate through skin. Large negative value indicates lesser skin permeability. This is directly correlated with molecular size and lipophilicity of compounds [52]. Log Kp values shown by all analyzed phytochemicals indicate lower skin permeability. An important aspect of developing therapeutics or their adjuvants is whether they are metabolized by Cytochromes thus reducing their efficacy or potentially interfering with concomitant therapy. Predictions showed that none of the phytochemicals of AR except, Isoagatharesinol have the potential to inhibit any of the major CYP isoforms (Table 3). Few TC phytochemicals may act as inhibitor of CYP1A2, CYP2D6 and CYP3A4 whereas few WS phytochemical may inhibit CYP2C9. These properties need to be considered during phytopharmaceutical development. However, these predictions may not be hold true for extracts as they contain multiple phytoconstituents because of which several properties might change.

COVID-19 pathogenesis mainly involves respiratory system and afterwards it leads to multiple organ failure based on patient related factors: sex, age, disease, individualization (PRF: SADI). As discussed earlier, diabetic, obese, asthmatic, geriatric, hypertensive population is more prone for COVID-19 [53]. These associated comorbidities of COVID-19 are being continually treated along with anti-SARS-COV-2 therapy. Here, we propose the use of Rasayana...
Table 3. *In silico* pharmacokinetic analysis of phytoconstituents from AR, TC, and WS.

| Herbs                  | Phytoconstituents | Predicted oral bioavailability | Predicted Drug-likeness | Pharmacokinetics                                                                 |
|------------------------|-------------------|---------------------------------|-------------------------|----------------------------------------------------------------------------------|
|                        |                   |                                 |                         | CYP§                                                                 | P-gp substrate | BBB permeability | GI absorption | Log Kp (cm/s) |
| Asparagus racemosus    | Muzanzagenin      | Orally bioavailable             | Y                       | N                             | Y                       | Y              | High          | -6.94         |
|                        | Asparanin A       | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -8.48         |
|                        |                   | polarity, solubility and size    |                         |                                |                          |                |               |               |
|                        |                   | axes lie outside pink region     |                         |                                |                          |                |               |               |
|                        | Asparagamine A    | Orally bioavailable             | Y                       | N                             | N                       | N              | High          | -6.95         |
|                        |                   |                                 |                         |                                |                          |                |               |               |
|                        | Isoagatharesinol  | Not orally bioavailable because  | Y                       | Y                             | CYP2D6, CYP3A4 only     | N              | N             | High          | -6.43         |
|                        |                   | saturation parameter does not    |                         |                                |                          |                |               |               |
|                        |                   | lie within pink area             |                         |                                |                          |                |               |               |
|                        | Rutin             | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.26        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Shatavarin I      | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -13.47        |
|                        |                   | of higher polarity, molecular    |                         |                                |                          |                |               |               |
|                        |                   | weight and flexibility           |                         |                                |                          |                |               |               |
|                        | Shatavarin IV     | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.53        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Shatavarin VI     | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.53        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Shatavarin VII    | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.97        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Shatavarin IX     | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.99        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Shatavarin X      | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -11.23        |
|                        |                   | of higher polarity, molecular    |                         |                                |                          |                |               |               |
|                        |                   | weight and flexibility           |                         |                                |                          |                |               |               |
| Tinosporacordifolia    | Berberine         | Orally bioavailable             | Y                       | Y                             | CYP1A2, CYP2D6, CYP3A4   | Y              | Y             | High          | -5.78         |
|                        | Columbamine       | Orally bioavailable             | Y                       | Y                             | CYP2D6, CYP3A4 only      | Y              | Y             | High          | -5.94         |
|                        | Menisperine       | Orally bioavailable             | Y                       | Y                             |                           | Y              | Y             | High          | -6.30         |
|                        | Magnoflorine      | Orally bioavailable             | Y                       | Y                             | CYP1A2, CYP3A4 only      | Y              | Y             | High          | -6.44         |
|                        | Tinosposaside     | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -9.13         |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Tinosporide       | Orally bioavailable             | Y                       | Y                             | CYP2D6 only              | Y              | N             | High          | -7.64         |
|                        | Tinocordiside     | Orally bioavailable             | Y                       | N                             | Y                       | N              | High          | -8.56         |
|                        | Syringin          | Orally bioavailable             | Y                       | N                             | Y                       | N              | Low           | -9.50         |
|                        | Columbin          | Orally bioavailable             | Y                       | N                             | Y                       | N              | High          | -6.95         |
|                        | 20-β-Hydroxy      | Orally bioavailable             | N                       | N                             | Y                       | N              | High          | -8.91         |
|                        | Ecdysone          |                                |                          |                                |                          |                |               |               |
| Withania somnifera     | Withacoagin       | Orally bioavailable             | Y                       | Y                             | CYP2C9 only              | Y              | N             | High          | -6.29         |
|                        | Withanolide B     | Orally bioavailable             | Y                       | Y                             |                           | Y              | N             | High          | -5.76         |
|                        | Withanamolide-12- | Orally bioavailable             | Y                       | Y                             |                           | Y              | N             | High          | -6.35         |
|                        | Deoxy            |                                |                          |                                |                          |                |               |               |
|                        | Withanoside IV    | Not orally bioavailable because  | N                       | N                             | Y                       | N              | Low           | -10.37        |
|                        |                   | of higher molecular weight and   |                         |                                |                          |                |               |               |
|                        |                   | polarity                         |                         |                                |                          |                |               |               |
|                        | Withanolide A     | Orally bioavailable             | Y                       | N                             | Y                       | N              | High          | -6.86         |

(Continued)
botanicals for COVID-19 prophylaxis (both pre and post COVID-19) as well as anti-SARS-CoV-2 activity. This can lead to the chances of HDIs, which may be harmful/beneficial/fatal [40]. Therefore, with the help of Swiss-ADME data (Table 3) and available published literature (S2 Table in S1 File) the probable pharmacokinetic HDI were explored. This showed that, whole plant extracts of these botanicals (especially those that are prepared according to the Ayurvedic procedure) do not inhibit main CYP isoforms such as, CYP1A2, CYP2D6 and CYP3A4. Various extracts of AR, TC and WS have IC\textsubscript{50} values >100 μg/mL for these CYP isoforms (S2 Table in S1 File). This indicates that, at higher concentrations (generally more than therapeutic dose), these extracts may produce pharmacokinetic HDI in vivo [54]. Based on the above results, these phytoconstituents or Rasayana botanicals may produce beneficial pharmacokinetic-pharmacodynamic interactions in vivo, with the anti-viral and disease-modifying drugs that are currently being prescribed for COVID-19.

**Discussion**

The understanding of pathophysiology of COVID-19 is emerging with increasing prevalence over the globe [55]. A wide variation in the patient population ranging from asymptomatic, to mild or moderate cases and severe cases (some showing relapse) is reported. Severe infections of SARS-CoV-2 lead to mortality due to severe acute respiratory syndrome accompanied with hypoxia followed by organ failure [6]. In general, we need to have drugs that are best prophylactic (pre and post COVID-19), immunomodulatory and adaptogenic in nature along with anti-SARS-CoV-2 action. Using in silico approaches, the present study shows that the selected Rasayana botanicals may have these all the actions and may be effective for management of COVID-19 (Fig 15). In the following sections we discuss in detail how these Rasayana botanicals and their phytoconstituents can be potential therapeutic adjuvants for the effective management of COVID-19.
Immune-bolstering activity

SARS-CoV-2 attacks pulmonary pneumocytes in alveolar sac for viral replication [7]. Typically, the immune response to viruses involve cytotoxic T-cells. The viral-infected host cells are recognised through binding of T-cell receptors (TCR) to MHC-I molecules. In case of viruses that escape from TCR recognition, physiological immune surveillance employs NK cells to eliminate virus infected cells. Cytotoxicity triggered by cytokines and other cytotoxic mediators induce infected cells to undergo apoptosis [56]. Our analysis showed that, Withanolides of WS may augment TCR signalling pathway by modulating NF-kappa-β regulators and theta type protein kinase C (PK-C). Withanolides may also involve in NK cell mediated cytotoxicity by modulating beta and gamma type PK-C. Rutin of AR and 20-hydroxyecdysone of TC may also help in destroying infected cells by regulating cytotoxicity mediator TNF-α. Magnoflorine and Menisperine of TC could modulate apoptosis through caspase proteins. They may involve in mediating innate immunity by regulating proteolytic cascade of complement system through coagulation factors. Shatavarsins of AR were predicted to modulate antigen processing and presentation through heat shock proteins. Withanolides may interact with integrin protein and interleukins to intensify non-inflammatory intestinal IgA secretion to neutralize virus. our It has also been reported that Withanone and Withaferin A may disrupt interactions between viral S-Protein and host receptor angiotensin converting enzyme (ACE) by binding...
to it [22]. Our docking studies also reveal that Withacoagin, 27-Hydroxywithanone and Withanolide-B have the potential to perform the same activity.

**Cytokine storm and inflammation**

If the body’s defence system or prophylactic treatment fails to control the viral entry and its clearance, the body activates strong inflammatory response leading to cytokine storm. Briefly, the internalization of SARS CoV-2 eventually leads to secretion of large quantities of pro-inflammatory cytokines [57]. This leads to engagement of immune cells at the infected site. The present data indicates potential of WS to interfere with chemokine signalling through beta and delta type PK-C and chemokine receptors. Similarly, IL-17 plays crucial role in acute and chronic inflammatory responses. The IL-17 signalling can be mitigated predominantly through heat shock protein by AR, glycogen synthase by TC, and prostaglandin synthase by WS. AR derived saponins and TC extract showed anti-inflammatory property by modulating pro-inflammatory cytokines along with other inflammatory modulators [58, 59]. WS extract also modulated cytokine expressions by inhibiting MAPK/NF-κB pathway [60]. This pathogenic reaction may become more complicated in co-morbidities like diabetes, asthma, hypertension, and obesity where inflammasome is already present [61]. This further activates this inflammatory cascade and COVID-19 progression. It has been reported that the Rasayana botanicals containing phytoconstituents like Withaferin-A have an ability to treat the inflammasome [19, 62–64].

**Increased vascular permeability**

The macrophage-mediated inflammatory cytokines cause contraction of endothelial cells of blood vessels which leads to increase in vascular permeability [65]. This increases migration of immune cells to occupy alveolar space. The proteins involved in trans-endothelial leukocyte migration are predicted to be modulate by Withanolides through our analysis. Integrin alpha-L (ITGAL) is one of the factor involved in trans-endothelial migration of leukocytes associated with COVID-19 pathogenesis [66]. Present data mining suggested ITGAL as putative target of 20-hydroxyecdysone from TC. Withaferin-A may inhibit and down-regulate vascular permeability factor i.e. VEGF [67, 68] and protects vascular barrier integrity inhibiting hyperpermeability induced by high-mobility group box 1 protein [69]. WS aqueous extract may inhibit histamine mediated endothelial contraction to avoid venular intercellular gaps [70, 71].

**Alveolar consolidation**

The engagement of immune cells and extent of cytokine secretion consolidate alveolar space. Production of surfactants by pneumocytes intensifies severity leading to dyspnoea or shortness of breath [72]. Withaferin A reduced accumulation of M1 type macrophages characterized by IL-6 and TNF-α [73]. The Rasayana botanicals affect physiological inflammatory response by downregulating proinflammatory mediators. This is accompanied with preventing immune cell accumulation at infected site i.e. alveolar space [74]. Therefore, Rasayana botanicals may evade alveolar consolidation keeping pneumocytes engaged in O2 transport as usual.

**Systemic inflammation-induced pyrexia**

In COVID 19, the cytokine storm (CS) results in excessive and uncontrolled release of pro-inflammatory mediators and cytokines. Clinically, it commonly presents as systemic inflammation and these inflammatory mediators act as a messengers to hypothalamus to increase body temperature through prostaglandin secretion [75]. Few studies have suggested that
Withaferin-A may circumvent pyrexia by downregulating COX-2 expression with simultaneous decrease in prostaglandin production [76, 77]. The newer understanding of SARS CoV2 pathogenesis is coming out gradually. Recent computational evidence has suggested, haemoglobin dissociation and iron imbalance by SARS-CoV-2 infection. This was supported by clinical observations of reduction in haemoglobin and increased erythrocyte sedimentation rate. This induces hypoxia leading to organ failure [78]. A systematic *in vivo* study of TC extract showed significant increase in levels of haemoglobin and erythrocyte count to maintain systemic iron homeostasis [79]. WS showed prophylactic effect in pulmonary hypertension characterised by hypoxia and inflammation [80]. The connection of hypoxia and inflammatory signals is well established through HIF1α gene [81]. Asparagus polysaccharides potentially inhibited HIF1α signalling which might ameliorate fatal systemic inflammation [82]. TC also exhibited anti-inflammatory effects in systemic models significantly [83]. Our data analysis also suggests probable action of AR, TC, and, WS in hematopoietic cell lineage through multiple protein targets involving integrin alpha-4 and CD38. It has now been clearly established that the adverse clinical outcomes in COVID-19 patients is associated with elevated IL-6 levels [84]. A case report using Tocilizumab (an anti-IL6 receptor antibody) defined an approach of mitigating risk of disease progression to target IL-6 [85, 86]. WS aqueous extract attenuated IL-6 in arthritis model to reduce inflammatory response. Active components of WS (Withanone and Withaferin-A) and AR (Shatavarin-IV) also inhibited production of IL-6 in *in vitro* system. It has also been reported that aqueous extract of TC protects against inflammation associated anaemia by modulating hepcidin expression, IL-6 and other pro-inflammatory cytokine cascade [79]. There is a clinical evidence showing immunocompromised patients are at high risk of developing fatal respiratory syndrome [87, 88]. In view of this, immunomodulating drugs are being considered beneficial for COVID-19 management [89]. The Ayurveda-based *Rasayana* botanicals are well known for their immunomodulatory activities [90]. The adaptogenic and regenerative properties of *Rasayana* botanicals help to maintain physiological homeostasis [91]. The effects of improving antibody titre, modulating systemic Th1/Th2 immunity underline the potential of AR as an immunoadjuvant [92]. TC and its phytoconstituents are capable immunomodulators through their multimodal actions [23, 93]. The significant immune-boosting potential of WS in several model systems makes it one of the best possible therapeutic adjuvants from traditional medicine [20, 94, 95].

**Predicted herb-drug interactions**

COVID-19 is a viral pandemic disease with no specific cure available so far. Few drugs and drug combinations are still under investigation for their efficacy in managing this fatal infection [96, 97]. Current treatment involves combination of previously available antiviral agents [98]. COVID-19 patients have co-morbidities like T2DM, hypertension, asthma, obesity, etc. are also being treated with these drugs along with their ongoing prescriptions [4]. Along with modern therapeutic agents, patients are also being treated with drugs from traditional medicinal system like Ayurveda [40, 99]. Thus, while using such diverse treatment regime, there is need for designing and executing detailed DDI (drug-drug interactions) and HDI (herb-drug interaction) studies for proposing safe, efficacious and beneficial combinations. DDI and HDI can be predicted by PK-PD pathways (with special focus on drug metabolising enzymes and transporters) of particular drug. Cytochrome P450 system (CYP’s) are major enzymes involved in catalysing biotransformation of administered drugs. CYP1A2, CYP3A4, CYP2C9 and CYP2D6 are involved in metabolism of around 80–90% of drugs [100]. Pharmacokinetic profiles of plant extracts considered in this study are not well established [101]. Data obtained from predictive web-based tools to evaluate the herb-drug PK-PD interactions...
analysis shows some phytochemicals may or may not inhibit main drug metabolizing enzymes (Table 3). This inference is also being supported by published in vitro studies on human liver microsomes using whole plant extracts of AR, TC, and WS (S2 Table in S1 File). IC50 values for all the extracts are > 100 μg/mL which seems to be a higher concentration than used in vivo [54, 102] (S4 Table in S1 File). Thus, we speculate that in vitro studies on human liver microsomes using whole plant extracts of AR, TC, and WS may not show any inhibition of these main CYP isoforms. However, there is a need to explore in vitro—in vivo HDI for rationalizing their use in pharmacotherapeutic management of COVID-19 [103]. We also recommend that HDI studies should be planned to focus on drugs used in the management COVID-19 and its associated comorbidities. The S5 Table in S1 File includes pharmacokinetic data of WHO Solidarity trial drugs and prescribed drugs (representative) for COVID-19 associated comorbidities (e.g. hypertension, asthma and T2DM). This data shows that, there is overlap for drug metabolizing enzymes especially among the allopathic drugs, indicating possible risky DDIs. Therefore, careful clinical validation is required. For instance, WHO Solidarity trial drugs (Remdesivir; Lopinavir/Ritonavir; Lopinavir/Ritonavir with Interferon beta-1a; and Chloroquine or Hydroxychloroquine) are being metabolized by CYP1A2, CYP3A4, CYP2C9, and/or CYP2D6 (S4 Table in S1 File). The commonly prescribed drugs for hypertension (Propranolol, Metoprolol, Telmisartan, Losartan) and T2DM (Glimepiride, and Pioglitazone) shares the same drug metabolizing enzymes (CYP1A2, CYP3A4, CYP2C9, and CYP2D6). This raises the concern for careful pharmacotherapeutic management. On the other hand, it can be predicted that there are very less chances of pharmacokinetic mediated HDI with the studied Rasayana botanicals as no such overlap has been found in our in-silico studies as well as published in vitro data.

In this study we explored the potential of Ayurveda based Rasayana drugs in COVID 19 management using in silico approaches and propose a library of phytoconstituents with the potential to be developed as phytopharmaceuticals. Appropriate pharmaceutics developability assessment needs to be done if any of these phytoconstituents are to be considered for phytopharmaceutical development. The in-silico pharmacokinetic data also shows that, Muzanzagenin is the main drug-like molecule from AR and it has also showed docking score better than -6.0 kcal/mol against all three protein targets of SARS-CoV-2. Majority of the key phytoconstituents show good oral bioavailability. All phytochemicals of TC were found to be drug-like substances. In case of WS phytochemicals, except Ashwagandhanolide, Withanoside V and Withanoside IV all were found to be drug-like molecules. Though, Ashwagandhanolide has shown highest docking score for all 3 SARS-CoV-2 protein targets its drug-likeness is an issue of concern and needs further detail investigations. On the other hand, the network pharmacology and docking data showed that there are very high chances of beneficial pharmacodynamic HDI for the effective pharmacotherapeutic management of COVID-19. At the same time, we cannot forget that the drug concentration plays the important role in both in-vitro and in vivo studies, therefore effective and safe clinical extrapolation based on experimentally validated data are warranted.

In conclusion, this study provides potential phytoconstituents for clinical application of Rasayana botanicals in prophylaxis because of their potential in inhibiting the replication of SARS-CoV-2. These botanicals can also be used as adjunct or mainstream treatment for COVID-19 when the disease is manifested with its symptom. The activities on immune mechanisms provide a sound logic for use of these botanicals in treatment. Some of the phytoconstituents have a possible role in arresting disease progression and preventing organ failure by reducing inflammatory responses. The adjunct use of these botanicals poses another important question of herb drug interactions which requires detailed experimental and clinical evidence.
Supporting information

S1 File.
(DOCX)

S1 Data.
(XLSX)

Acknowledgments

Authors are also thankful to Dr Pramod Kumar (NCDC, Delhi) and Dr. Pratiksha Jadun (NARI, Pune) for providing valuable suggestions about SARS-CoV-2 druggable targets. The authors are also thankful to Prof Vishnu Joglekar, Dr. Supriya Zende, Dr. Gayatri Fadnavis and Miss. Shruti Kougli for their timely assistance with this work.

Author Contributions

Conceptualization: Swapnil Borse, Manali Joshi, Preeti Chavan-Gautam, Girish Tillu.

Data curation: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Sneha Sagar, Girish Tillu.

Formal analysis: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani.

Funding acquisition: Swapnil Borse, Manali Joshi, Preeti Chavan-Gautam, Lal Hingorani, Girish Tillu.

Investigation: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Aniket Marathe, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani, Girish Tillu.

Methodology: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Aniket Marathe, Sneha Sagar, Aboli Girme, Lal Hingorani.

Project administration: Swapnil Borse, Manali Joshi, Preeti Chavan-Gautam.

Resources: Swapnil Borse, Manali Joshi, Preeti Chavan-Gautam, Lal Hingorani, Girish Tillu.

Supervision: Swapnil Borse, Manali Joshi, Preeti Chavan-Gautam.

Validation: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani, Girish Tillu.

Visualization: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Aniket Marathe, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani, Girish Tillu.

Writing – original draft: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani.

Writing – review & editing: Swapnil Borse, Manali Joshi, Akash Saggam, Vedika Bhat, Safal Walia, Aniket Marathe, Sneha Sagar, Preeti Chavan-Gautam, Aboli Girme, Lal Hingorani, Girish Tillu.

References

1. WHO announces COVID-19 outbreak a pandemic. [cited 23 Apr 2020]. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020
2. Q&A on coronaviruses (COVID-19). [cited 23 Apr 2020]. Available: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses

3. Wu Z MJ. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020.

4. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019—United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 382–386. https://doi.org/10.15585/mmwr.mm6913e2 PMID: 32240123

5. Du L, He Y, Zhou Y, Liu S, Zheng BJ JS. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7: 226–36. https://doi.org/10.1038/nrmicro2090 PMID: 19198616

6. Weiss SR, Navas-Martin S. Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiol Mol Biol Rev. 2005; 69: 635–664. https://doi.org/10.1128/MMBR.69.4.635-664.2005 PMID: 16339739

7. Chow K-C, Hsiao C-H, Lin T-Y, Chen C-L, Chiou S-H. Detection of severe acute respiratory syndrome-associated coronavirus in pneumocytes of the lung. Am J Clin Pathol. 2004; 121: 574–80. https://doi.org/10.1016/j.ajcp.2004.06.003

8. Patwardhan B, Chavan-gautam P, Gautam M, Tillu G, Chopra A. Ayurveda rasayana in prophylaxis of COVID-19. 19: 1–3.

9. BJGMC Pune Protocol for Treatment of Confirmed COVID 19 (+) Hospitalized Patients. 19: 1–5.

10. Yazdany J, Kim AJU. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020; 19–21. https://doi.org/10.7326/M20-1334 PMID: 32253318

11. WHO. “Solidarity” clinical trial for COVID-19 treatments. 2020 [cited 20 Apr 2020]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

12. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020; 202004168. https://doi.org/10.1073/pnas.2004168117 PMID: 32253318

13. Gauvret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949 PMID: 32205204

14. Garcia-Cremades M, Solanas BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1856 PMID: 32285930

15. Patwardhan B. The quest for evidence-based Ayurveda: lessons learned. Curr Sci. 2012.

16. Roy A, Patwardhan B, Chaguturu R. Reigniting pharmaceutical innovation through holistic drug targeting. Drug Discov World. 2016; 17: 45–55.

17. Bhushan Patwardhan RC. Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting. Acad Press. 2016.

18. Patwardhan B, Vaidya ADB. Natural products drug discovery: Accelerating the clinical candidate development using reverse pharmacology approaches. NISCAIR Online Period Repos. 2010; 220–227. PMID: 21049674

19. Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities REVIEWS. 2005;10.

20. Saggam A, Tillu G, Dixit S, Chavan-Gautam P, Borse S, Joshi K, et al. Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer. J Ethnopharmacol. 2020; 255: 112759. https://doi.org/10.1016/j.jep.2020.112759 PMID: 32173425

21. Balkrishna A., Pokhrel S., Singh J., Varshney A. Withanone from Withania somnifera May Inhibit Novel Coronavirus (COVID-19) Entry by Disrupting Interactions between Viral S-Protein Receptor Binding Domain and Host ACE2 Receptor. Virol J. 2020.

22. Balkrishna A, Pokhrel S, Singh J, Varshney A. Withanone from Withania somnifera May Inhibit Novel Coronavirus (COVID-19) Entry by Disrupting Interactions between Viral S-Protein Receptor Binding Domain and Host ACE2 Receptor. Virol J. 2020. https://doi.org/10.21203/RS.3.RS-17806/V1

23. Ghosh S, Saha S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012; 31: 151. https://doi.org/10.4103/0257-7941.107344 PMID: 23661861

24. Girme A, Saste G, Pawar S, Balasubramaniam AK, Musande K, Darji B, et al. Investigating 11 Withanosides and Withanolides by UHPLC-PDA and Mass Fragmentation Studies from Ashwagandha
25. Ahmed SM, Manhas LR, Verma V, Khajuria RK. Quantitative determination of four constituents of Tinospora sps. by a reversed-phase HPLC-UV-DAD method. Broad-based studies revealing variation in content of four secondary metabolites in the plant from different eco-geographical regions of India. J Chromatogr Sci. 2006; 44: 504–509. https://doi.org/10.1093/chromsci/44.8.504 PMID: 16959127

26. Patil D, Gautam M, Gairola S, Jadhav S, Patwardhan B. HPLC/Tandem mass spectrometric studies on steroidal saponins: An example of quantitative determination of shatavarin IV from dietary supplements containing Asparagus racemosus. J AOAC Int. 2014; 97: 1497–1502. https://doi.org/10.5740/jaoacint.13-382 PMID: 25632427

27. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res. 2019; 47: D1102–D1109. https://doi.org/10.1093/nar/gky1033 PMID: 30371825

28. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007; 35: D198–D201. https://doi.org/10.1093/nar/gkl999 PMID: 17145705

29. The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2016. https://doi.org/10.1093/nar/gkw1099 PMID: 27899622

30. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017; 45: D353–D361. https://doi.org/10.1093/nar/gkw1092 PMID: 27999662

31. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498–2504. https://doi.org/10.1101/gr.1239303 PMID: 14957658

32. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS OA. AutoDock4 and AutoDock-Tools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30: 2785–91. https://doi.org/10.1002/jcc.21256 PMID: 19399780

33. Dallakian S OA. Small-molecule library screening by docking with PyRx. InChemical Biol. 2015; 243–250. https://doi.org/10.1007/978-1-4939-2269-7_19 PMID: 25618350

34. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (80-). 2020. https://doi.org/10.1126/science.abb7498 PMID: 32277040

35. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (80-). 2020; 367: 1444–1448. https://doi.org/10.1126/science.abb2762 PMID: 32132184

36. O'Boyle NM, Banck M, James CA, Morley C, Vandermersch T, Hutchison GR. Open Babel. J Cheminform. 2011; 3: 1–14. https://doi.org/10.1186/1758-2946-3-1 PMID: 21214931

37. Pronk S, Pałl S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29: 845–854. https://doi.org/10.1093/bioinformatics/btt055 PMID: 23407358

38. Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. Journal of computational chemistry. United States; 2008. pp. 1859–1865. https://doi.org/10.1002/jcc.20945 PMID: 18351591

39. Huang J, MacKerell ADJ. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013; 34: 2135–2145. https://doi.org/10.1002/jcc.23354 PMID: 23832629

40. Borse S, Singh D, Nivsarkar M. Understanding the relevance of herb–drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J. 2019; 4: e15. https://doi.org/10.1016/j.pbj.2019.e00015 PMID: 31595257

41. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7: 1–13. https://doi.org/10.1038/s41598-016-0028-x PMID: 28127051

42. Girme A, Saste G, Balasubramaniam AK, Pawar S, Ghule C, Hingorani L. Assessment of Curcuma longa extract for adulteration with synthetic curcumin by analytical investigations. J Pharm Biomed Anal. 2020; 191: 113603. https://doi.org/10.1016/j.jpba.2020.113603 PMID: 32957065

43. Patwardhan B, Chandran U. Network Ethnopharmacology Approaches for Formulation discovery. NISCAIR Online Period Repos. 2015.

44. Chandran U, Patwardhan B. Network ethnopharmacological evaluation of the immunomodulatory activity of Withania somnifera. J Ethnopharmacol. 2017; 197: 250–256. https://doi.org/10.1016/j.jep.2016.07.080 PMID: 27487266
45. Tillu G, Chaturvedi S, Chopra A, Patwardhan B. Public Health Approach of Ayurveda. 2020; X: 1–5. https://doi.org/10.1089/acm.2020.0129 PMID: 32310670

46. Mukherjee PK, Banerjee S, Kar A. Exploring synergy in ayurveda and traditional Indian systems of medicine. Synergy. Elsevier GmbH; 2018. pp. 30–33. https://doi.org/10.1016/j.synres.2018.10.003

47. Yuan H, Ma Q, Cui H, Liu G, Zhao X, Li W, et al. How can synergism of traditional medicines benefit from network pharmacology? Molecules. MDPI AG; 2017. https://doi.org/10.3390/molecules22071135 PMID: 28686181

48. Joshi M, Rajapathak SN, Narwade SC, Deobagkar D. Ensemble-Based Virtual Screening and Experimental Validation of Inhibitors Targeting a Novel Site of Human DNMT1. Chem Biol Drug Des. 2016; 5–16. https://doi.org/10.1111/cbdd.12741 PMID: 26850820

49. Hopkins AL, Keserü GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014; 13: 105–121. https://doi.org/10.1038/nrd4163 PMID: 24481311

50. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020; 117: 6771–6776. https://doi.org/10.1073/pnas.1922083117 PMID: 32054787

51. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020. https://doi.org/10.1016/j.apsb.2020.02.008 PMID: 32292689

52. Potts RO GR. Predicting skin permeability. Pharm Res. 1992; 9: 663–9. https://doi.org/10.1023/a:1015810312465 PMID: 1608900

53. Zain S, Chong JH, Sankaranarayanan V HA. COVID-19 and Multi-Organ Response. Curr Probl Cardiol. 2020.

54. Borse SP, Kamble BB. Effects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system. J Integr Med. 2015; 13: 165–172. https://doi.org/10.1016/S2095-4964(15)60173-X PMID: 26006029

55. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020; 12. https://doi.org/10.3390/v12040372 PMID: 32230900

56. Braci le TJ, Hahn YS. Immunity to viruses. Immunological Reviews. NIH Public Access; 2013. pp. 5–12. https://doi.org/10.1111/imr.12109 PMID: 23947343

57. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. Lancet Publishing Group; 2020. pp. 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0 PMID: 32192578

58. Tiwari N, Gupta VK, Pandey P, Patel DK, Banerjee S, Darokar MP, et al. Adjuvant effect of Asparagus racemosus Willd. derived saponins in antibody production, allergic response and pro-inflammatory cytokine modulation. Biomed Pharmacother. 2017; 96: 555–561. https://doi.org/10.1016/j.biopha.2016.11.087 PMID: 28024292

59. Tiwari M, Dwivedi UN, Kakkar P. Tinospora cordifolia extract modulates COX-2, iNOS, ICAM-1, pro-inflammatory cytokines and redox status in murine model of asthma. J Ethnopharmacol. 2014; 153: 326–337. https://doi.org/10.1016/j.jep.2014.01.031 PMID: 24556222

60. Sikandar A, Shinomiya T, Nagahara Y. Ashwagandha root extract exerts anti-inflammatory effects in HaCaT cells by inhibiting the MAPK/NF-κB pathways and by regulating cytokines. Int J Mol Med. 2018; 42: 425–434. https://doi.org/10.3892/ijmm.2018.3608 PMID: 29602265

61. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8: e21. https://doi.org/10.1016/S2213-2600(20)30116-6 PMID: 32171062

62. Kaul SC WR. Science of Ashwagandha: Preventive and Therapeutic Potentials. Springer, Cham; 2017.

63. Chulet R, Pradhan P. A review on rasayana. Pharmacogn Rev. 2009; 3: 229–234.

64. Anchi P, Khurana A, Bale S, Godugu C. The Role of Plant-derived Products in Pancreatitis: Experimental and Clinical Evidence. Phyther Res. 2017; 31: 591–623. https://doi.org/10.1002/ptr.5792 PMID: 28295751

65. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020; 9: e016219. https://doi.org/10.1161/JAHA.120.016219 PMID: 32233755

66. Ostermann G, Weber KSC, Zernecke A, Schröder A, Weber C. JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002; 3: 151–158. https://doi.org/10.1038/ni755 PMID: 11812992
86. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19

87. Fung M BJ. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021; 72: 340–50. https://doi.org/10.1093/cid/ciaa863 PMID: 33501974

PLOS ONE | https://doi.org/10.1371/journal.pone.0248479 June 11, 2021 32 / 33
88. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32007143

89. Russell B, Moss C, George G, Santalallia A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecanercamedicalscience. 2020;14. https://doi.org/10.3332/ecancer.2020.10205 PMID: 32256705

90. Balasubramani SP, Venkatasubramanian P, Kukkupuni SK, Patwardhan B. Plant-based Rasayana drugs from Ayurveda. Chinese Journal of Integrative Medicine. 2011, pp. 88–94. https://doi.org/10.1007/s11655-011-0659-5 PMID: 21390573

91. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phyth er Res. 1999; 13: 275–291. https://doi.org/10.1002/(SICI)1099-1573(199906)13:4<275::AID-PTR510>3.0.CO;2-S PMID: 10404532

92. Gautam M, Saha S, Bani S, Kaul A, Mishra S, Patil D, et al. Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: implications for immunoadjuvant potential. J Ethnopharmacol. 2009; 121: 241–7. https://doi.org/10.1016/j.jep.2008.10.028 PMID: 19038322

93. Sharma U, Bala M, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active compounds from Tinospora cordifolia. J Ethnopharmacol. 2012; 141: 918–926. https://doi.org/10.1016/j.jep.2012.03.027 PMID: 22472109

94. Bani S, Gautam M, Sheikh FA, Khan B, Satti NK, Suri KA, et al. Selective Th1 up-regulating activity of Withania somnifera aqueous extract in an experimental system using flow cytometry. J Ethnopharmacol. 2006; 107: 107–115. https://doi.org/10.1016/j.jep.2006.02.016 PMID: 16603328

95. Agarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol. 1999; 67: 27–35. https://doi.org/10.1016/s0378-8741(99)00065-3 PMID: 10616957

96. Profile D, Pharmaceuticals OB, Pharmaceuticals DB, Diseases I. Galidesivir—BioCryst Pharmaceuticals. 2020.

97. Profile D, Sciences OG, Hospital DCF, Sciences G. Remdesivir—Gilead Sciences. 2020.

98. Sanders JM, Monogue ML, Jodlowski TZ, Cutchell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020;2019. https://doi.org/10.1001/jama.2020.6019 PMID: 32282022

99. Goa to be the first state to integrate allopathy with Ayurveda to treat COVID-19 patients. Available: https://www.thehindubusinessline.com/news/goa-to-be-the-first-state-to-integrate-allopathy-with-ayurveda-to-treat-covid-19-patients/article31315136.ece

100. Zanger UM, Schwab M. Pharmacology & Therapeutics Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138: 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007 PMID: 23333322

101. Williamson EM, Driver S BK. Stockley’s herbal medicines interactions: a guide to the interactions of herbal medicines, dietary supplements and nutraceuticals with conventional medicines.

102. Patil D, Gautam M, Gairola S, Jadhav S, Patwardhan B. Effect of botanical immunomodulators on human CYP3A4 inhibition: Implications for concurrent use as adjuvants in cancer therapy. Integr Cancer Ther. 2014; 13: 167–175. https://doi.org/10.1177/1534735413503551 PMID: 24105360

103. Patwardhan B, Vaidya AD, Chorghade M JS. Reverse pharmacology and systems approaches for drug discovery and development. Curr Bioact Compd. 2008; 4: 201–12.